Publication | Closed Access

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Open-label TrialHepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitisVirologyLiver DiseaseAntiviral DrugMedicineEgyptian PatientsPhase 3